March 2025, Self-screen’s HPV Risk Assay recommended to the Uruguayan Ministry of Health for cervical cancer screening.

November 2024, Launch of Methylated DNA Control Sample

November 2024, Gamidor Diagnostics receives distribution rights from Self-screen to market PreCursor-M family of methylation-specific molecular assays to identify high risk for HPV induced cancers.

March 2024, Self-screen and Fujirebio Europe launch PreCursor-M AnoGYN assay (RUO) for methylation testing in anal specimens

February 2024, Self-sampling workflow NeuMoDx HPV assay validated for screening purposes

January 2024, SELF-SCREEN SUCCESFULLY ISO13485 RE-ACCREDITED